Article

Breast Cancer Research and Treatment

, Volume 61, Issue 2, pp 145-150

Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer

  • Hitoshi OkamuraAffiliated withPsycho-Oncology Division, National Cancer Center Research Institute Eastthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)
  • , Noboru YamamotoAffiliated withthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)Department of Medical Oncology, National Cancer Center Hospital
  • , Toru WatanabeAffiliated withthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)Department of Medical Oncology, National Cancer Center Hospital
  • , Noriyuki KatsumataAffiliated withthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)Department of Medical Oncology, National Cancer Center Hospital
  • , Shigemitsu TakashimaAffiliated withthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)Department of Surgery, National Shikoku Cancer Center Hospital
  • , Isamu AdachiAffiliated withthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)Department of Medical Oncology, National Cancer Center Hospital
  • , Akira KugayaAffiliated withPsycho-Oncology Division, National Cancer Center Research Institute Eastthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)
  • , Tatsuo AkechiAffiliated withPsychiatry Division, National Cancer Center Hospital
  • , Yosuke UchitomiAffiliated withPsycho-Oncology Division, National Cancer Center Research Institute Eastthe Breast Cancer Study Group, the Japan Clinical Oncology Group (JCOG)

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose: To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician.

Patientsandmethods: Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized phase III trial (Japan Clinical Oncology Group (JCOG) Study 8808) were asked whether they understood their own disease after being given information about the clinical trial. They were classified into two groups on the basis of whether they understood or not. We estimated their survival after the time of registration and derived relative hazard ratios from Cox's proportional hazards model.

Results: There were 190 patients in the ‘better understanding’ group and 24 in the ‘poor understanding’ group. Median survival times after registration were 28.3 and 16.1 months, respectively. The ‘better understanding’ group showed a significant difference from the ‘poor understanding’ group (p=0.016). In multivariate regression analysis, patients who did not understand still showed poorer survival than those who understood (hazard ratio = 2.09; 95% confidence interval (CI) 1.16–3.78; p=0.014)

clinical trial informed consent metastatic breast cancer survival understanding